Answers are grounded in this paper and cite their sources.
SUMMARY Antipsychotics are increasingly prescribed to children with intellectual disabilities for behaviours that challenge. In the UK, only risperidone is licensed in this population, solely for short-term treatment of persistent aggression in conduct disorder in children with subaverage intellectual functioning. Yet antipsychotics are prescribed routinely, indefinitely and off-label for behavioural control, despite weak evidence, serious harms and problematic ethical justification. This article argues such prescribing is unjustifiable. At these doses, antipsychotics act mainly by sedation and suppressing the capacity to express distress, desire and objection. In children often unable to consent or report side-effects, and dependent on adults whose interests may differ, this is pharmacological restraint, with poorly monitored cumulative metabolic, neurological and cardiovascular harms. Behaviours that challenge communicate unmet need. Systematic biological assessment often identifies treatable causes; psychosocial interventions and treatment of physical health problems achieve comparable outcomes without adverse effects. The article presents an assessment framework, deprescribing guidance and good practice points that put the child’s interests are paramount.
No takes yet. Share an insight, caveat, or question.
Annie Swanepoel (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: